Affimed (NASDAQ:AFMD) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Affimed (NASDAQ:AFMD) have received an average rating of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $16.00.

Several brokerages recently weighed in on AFMD. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Affimed in a report on Friday, November 15th. Finally, Stifel Nicolaus cut their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of Affimed during the 3rd quarter worth $44,000. Choreo LLC bought a new stake in shares of Affimed in the 2nd quarter valued at about $54,000. FMR LLC grew its position in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the last quarter. Intellectus Partners LLC raised its stake in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Stock Down 4.3 %

NASDAQ AFMD opened at $2.87 on Friday. Affimed has a 1-year low of $2.61 and a 1-year high of $8.95. The business’s fifty day moving average price is $3.36 and its 200-day moving average price is $4.41. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The company had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $1.67 million. Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. As a group, research analysts anticipate that Affimed will post -4 EPS for the current year.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.